Drugs / GSK2231392A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01777295 | Feb 2013 → May 2016 | hepatitis B virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2231392A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01777295 ↗ |
| Modality | Vaccine | “model vaccine containing hepatitis B surface antigen and AS01 in healthy adults (NCT01777295).” PMID 39083587 ↗ Jul 2024 |
| Route | Intramuscular | “Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.” NCT01777295 ↗ |